Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Ahn, Inhye E., Farooqui, Mohammed Z. H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E. M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969380/
https://ncbi.nlm.nih.gov/pubmed/29483101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-820910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados